American Century Companies Inc. Boosts Holdings in ADMA Biologics Inc $ADMA

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

American Century Companies Inc. boosted its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 12.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,252,362 shares of the biotechnology company's stock after acquiring an additional 478,800 shares during the period. American Century Companies Inc. owned 1.79% of ADMA Biologics worth $84,367,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Skandinaviska Enskilda Banken AB publ purchased a new stake in ADMA Biologics during the 1st quarter valued at approximately $35,000. Tsfg LLC purchased a new stake in ADMA Biologics during the 1st quarter valued at approximately $51,000. Harvest Fund Management Co. Ltd purchased a new stake in ADMA Biologics during the 1st quarter valued at approximately $52,000. Farther Finance Advisors LLC grew its holdings in ADMA Biologics by 1,149.1% during the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after buying an additional 2,505 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in ADMA Biologics during the 4th quarter valued at approximately $85,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Price Performance

Shares of ADMA stock traded down $0.20 on Thursday, reaching $17.10. The company's stock had a trading volume of 1,902,779 shares, compared to its average volume of 3,132,921. The stock's fifty day simple moving average is $18.06 and its 200-day simple moving average is $18.86. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $4.08 billion, a price-to-earnings ratio of 19.88 and a beta of 0.38.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. During the same period last year, the firm posted $0.13 earnings per share. ADMA Biologics's revenue for the quarter was up 13.8% compared to the same quarter last year. Analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ADMA has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial increased their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $27.67.

Insider Activity at ADMA Biologics

In related news, Director Jerrold B. Grossman sold 10,000 shares of the firm's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the transaction, the director directly owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. This trade represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the transaction, the director directly owned 87,330 shares of the company's stock, valued at $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 455,621 shares of company stock valued at $9,461,633. 3.50% of the stock is owned by corporate insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.